Salvatore Petta1, Giuseppe Cabibbo1, Marco Enea2, Fabio Salvatore Macaluso1, Antonella Plaia2, Raffaele Bruno3, Antonio Gasbarrini4, Savino Bruno5, Antonio Craxì1, Calogero Cammà6. 1. Section of Gastroenterology, Di.Bi.M.I.S., University of Palermo, Italy. 2. Department of Economic, Business and Statistic Science (SEAS), University of Palermo, Palermo, Italy. 3. Division of Infectious and Tropical Diseases, Foundation IRCCS San Matteo Hospital, University of Pavia, Italy. 4. Gastroenterology Unit, Catholic University, Rome, Italy. 5. Department of Internal Medicine, A.O. Fatebenefratelli e Oftalmico, Milan, Italy. 6. Section of Gastroenterology, Di.Bi.M.I.S., University of Palermo, Italy. Electronic address: calogero.camma@unipa.it.
Abstract
BACKGROUND: We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy. METHODS: Cost-effectiveness analysis performed according to data from the available published literature. The target population was composed of untreated Caucasian patients, aged 50 years, with genotype 1 chronic hepatitis C, and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian National Health Service. Outcomes included discounted costs (in euro, at 2013 value), life-years gained, quality-adjusted life year, and incremental cost-effectiveness ratio. The robustness of the results was evaluated by multivariable probabilistic sensitivity analyses. RESULTS: According to the baseline predictors of sustained virological response (genotype 1b, low viral load, fibrosis F0-F3, and body mass index) and the 1Log drop of HCV-RNA after the dual therapy lead-in period, boceprevir was cost-effective in different patient profiles. CONCLUSIONS: In untreated genotype 1b chronic hepatitis C patients, the cost-effectiveness of boceprevir-based triple therapy widely ranges according to different profiles of sustained virological response predictors, allowing optimization and personalization of triple therapy.
BACKGROUND: We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy. METHODS: Cost-effectiveness analysis performed according to data from the available published literature. The target population was composed of untreated Caucasian patients, aged 50 years, with genotype 1 chronic hepatitis C, and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian National Health Service. Outcomes included discounted costs (in euro, at 2013 value), life-years gained, quality-adjusted life year, and incremental cost-effectiveness ratio. The robustness of the results was evaluated by multivariable probabilistic sensitivity analyses. RESULTS: According to the baseline predictors of sustained virological response (genotype 1b, low viral load, fibrosis F0-F3, and body mass index) and the 1Log drop of HCV-RNA after the dual therapy lead-in period, boceprevir was cost-effective in different patient profiles. CONCLUSIONS: In untreated genotype 1b chronic hepatitis Cpatients, the cost-effectiveness of boceprevir-based triple therapy widely ranges according to different profiles of sustained virological response predictors, allowing optimization and personalization of triple therapy.
Authors: Andrew J Leidner; Harrell W Chesson; Philip R Spradling; Scott D Holmberg Journal: Appl Health Econ Health Policy Date: 2017-02 Impact factor: 2.561
Authors: Rodolfo Castro; Louise Crathorne; Hugo Perazzo; Julio Silva; Chris Cooper; Jo Varley-Campbell; Daniel Savignon Marinho; Marcela Haasova; Valdilea G Veloso; Rob Anderson; Chris Hyde Journal: BMC Med Res Methodol Date: 2018-06-13 Impact factor: 4.615
Authors: Nadia A Nabulsi; Michelle T Martin; Lisa K Sharp; David E Koren; Robyn Teply; Autumn Zuckerman; Todd A Lee Journal: Front Pharmacol Date: 2020-11-13 Impact factor: 5.810
Authors: Kirsten Y Westerhout; Walter Bouwmeester; Inge Duchesne; Marta Pisini; Marjanne A Piena; Francesco Damele; Beatrice Gueron; Maarten Treur; Jonathan Belsey Journal: Clinicoecon Outcomes Res Date: 2017-02-27